[DOI] [PubMed] [Google Scholar] Xu X, Lemaire C, Grzych JM, Pierce RJ, Raccurt M, Mullier F, Zerimech F, Decavel JP, Peyrol S, Liu J, Fontaine J, Lafitte S, Capron A and Cesbron JY
In the results overview below, the antioxidants, vitamins and minerals in green are in the optimal range, the yellow is borderline and the red are nutrients she needs more of
206Most executives spend their careers looking for the next sure thing.Jojo Malolos did the opposite.After helping build some of the most important names in digital banking and fintechfrom Smart Money (now Maya) to Wing Bank and GoTyme Bankhe made a surprising decision: to take over PayMongo at one of the most challenging moments in its history.Why would a veteran fintech leader leave a comfortable position and walk straight into a turnaround situation?What did he see in PayMongo that others didn't?And how do you rebuild a company when the market, your customers, and even your own team are looking for reasons to doubt?In this episode of The RJ Ledesma Podcast, Jojo shares the inside story behind PayMongo's transformationfrom stabilizing the organization and rebuilding confidence to creating a roadmap for sustainable growth in one of the country's most competitive industries.This isn't just a conversation about fintech.It's a masterclass in leadership, resilience, change management, and making bold bets when everyone else is running the other way.If you're a founder, entrepreneur, executive, or anyone leading through uncertainty, you'll want to hear this one.Because great leaders don't inherit perfect situations.They build great companies from imperfect ones. Watch the full episode of The RJ Ledesma Podcast now.#RJLedesmaPodcast #JojoMalolos #PayMongo #Fintech #Leadership #TurnaroundStory #Entrepreneurship #DigitalBanking #BusinessPodcastFor any collaboration, brand partnership, and campaign run inquiries, e-mail us at [email protected]
The Matthews correlation coefficient (MCC) algorithm of the Cytohubba plug-in in Cytoscape software was employed to pinpoint QCTs top target proteins
Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks FDA
If cold is good, wouldn't colder be better
